United Therapeutics has been closely monitoring the rapidly evolving situation around Coronavirus (COVID-19). We are dedicated to providing ongoing support for patients and healthcare providers, and ensuring an uninterrupted supply of drug product.

Cadd-MS 3

Traditional, all-in-one SC Remodulin pump

Remodulin CADD-MS® 3 Pump

With its compact size and integrated functions, CADD-MS 3 has been used to deliver Remodulin subcutaneously for over 18 years.

Benefits of CADD-MS 31

  • Only 3.2" x 1.8" x 0.95"—about the size of a pager
  • The CADD-MS 3 can be clipped to a waistband, held in a pouch, or hidden under clothing
  • Programmed directly on the pump
  • Water-resistant casing
  • Each cartridge holds up to a 3-day supply of Remodulin
  • Appropriate for patients who are titrating or on a stable dose of Remodulin

Training

United Therapeutics Representatives are available if you need additional information or training on the administration of Remodulin.

Request a Rep

Download the Remodulin Referral Form and specify that your patient is to receive the CADD-MS 3 pump.

View Specialty Pharmacy Services (SPS) for patients using IV and SC Remodulin.

IV=intravenous; SC=subcutaneous.

Important Safety Information

Warnings and Precautions

Adverse Reactions

Drug Interactions

Specific Populations

Indication

Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%).

In patients with PAH requiring transition from epoprostenol, Remodulin is indicated to diminish the rate of clinical deterioration. Consider the risks and benefits of each drug prior to transition.

REMISIhcpOct19

Please see accompanying Full Prescribing Information for Remodulin.

For additional information, visit www.remodulin.com or call Customer Service Line at 1-877-UNITHER (1-877-864-8437).

Important Safety Information

Warnings and Precautions

Adverse Reactions

Drug Interactions

Specific Populations

Indication

Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%).

In patients with PAH requiring transition from epoprostenol, Remodulin is indicated to diminish the rate of clinical deterioration. Consider the risks and benefits of each drug prior to transition.

REMISIhcpOct19

Please see accompanying Full Prescribing Information for Remodulin.

For additional information, visit www.remodulin.com or call Customer Service Line at 1-877-UNITHER (1-877-864-8437).

Reference: 1. Operator’s Manual: CADD-MS 3 Ambulatory Infusion Pump. St. Paul, MN: Smiths Medical; 2008.